— Know what they know.
Not Investment Advice
Also trades as: FYB.DE (XETRA) · $vol 0M

0W4N.L LSE

Formycon AG
1W: +0.6% 1M: -1.2% 3M: -2.2% YTD: -17.9% 1Y: -22.7% 3Y: -66.5%
€19.10 ($21.40)
-0.08 (-0.42%)
 
Weekly Expected Move ±2.3%
€18 €19 €19 €20 €20
LSE · Healthcare · Biotechnology · Tech Score Sell · Power 42 · €339.0M mcap · 13M float · 0.0034% daily turnover

Cash Flow Trends

Operating Cash Flow
-$23M -135.8% ▼
Capital Expenditures
$30M -2809.6% ▼
5Y CAGR: +96.9%
Free Cash Flow
-$53M -388.7% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$15M -14.0% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income-$6M-$13M$36M$76M-$126M
Depreciation & Amort.$915K$2M$2M$2M$139M
Stock-Based Comp.$785K$774K$535K$2M$2M
Change in Working Capital-$264K-$2M-$3M-$13M-$12M
Other Non-Cash Items-$53K$5M-$55M-$76M-$26M
Operating Cash Flow-$5M-$14M-$19M-$10M-$23M
— Investing Activities —
Capital Expenditures-$650K-$941K-$27M-$21M-$2M
Acquisitions (Net)$69K$0$1M$0$0
Investment Purchases$0-$3M-$11M$0$0
Investment Sales$0$0$37M$0$0
Other Investing-$69K$0-$37M$4M$86K
Investing Cash Flow-$650K-$4M-$37M-$17M-$1M
— Financing Activities —
Net Debt Issuance-$954K-$1M$40M-$23M-$41M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$954K$0-$908K-$3M-$2M
Financing Cash Flow$26M$491K$41M$44M$39M
Net Change in Cash$20M-$17M-$15M$17M$15M
Cash End of Period$42M$25M$10M$27M$42M
Free Cash Flow-$6M-$14M-$46M-$11M-$53M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms